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No reported disclosures. Methods. This retrospective descriptive epidemiology study identified patients with DLIs in the Vanderbilt LVAD registry or INTERMACS data from January 2013 to August 2017. Driveline infections met International Society for Heart and Lung Transplantation definitions in addition to positive driveline drainage, blood, or sternal wound culture. Relapse included a DLI with an organism associated with previous DLI in the preceding year and similar MICs or new resistance to an antibiotic that was utilized. The LVAD registry and chart review were utilized to collect data. Patients were followed until transplant, death, or August 1, 2017.
Left Ventricular Assist Device Driveline Infections: Relapsed Infections and Minimum Inhibitory Concentration Changes
Results. A total of 330 patients underwent LVAD implantation. Thirty (9%) met criteria for DLI. Median duration of follow-up was 26 months (IQR 16, 39). There were 74 courses of infection, 40 new infections, and 34 relapsed infections. Median time to first DLI was 171 days (IQR 83, 403) . Most common organisms in new DLIs were S. aureus (MRSA 11, MSSA 10), diptheroids (6), coagulase-negative staphylococci (6), and P. aeruginosa (5). S. aureus was the most common pathogen in patients with DLI associated bacteremia (n = 16) as well as relapsed infection (n = 11). There were 42 MIC changes in nine patients with relapsed infections from S. aureus, P. aeruginosa, and mycobacterium. Median time to first MIC change was 56 days (IQR 36, 88) and type of MIC change was an increase in five cases, decrease in two cases, and both increase and decrease in two cases. Time to first relapse from initial infection was longer in those who received suppression, 60 days vs. 83 days, P = 0.047.
Conclusion. Few patients had DLIs, but relapsed infections were more common with S. aureus and P. aeruginosa. MIC changes were quite variable and may not be the major contributor to relapsed infection.
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Infectious Complications in Adult Patients with Hemophagocytic Lymphohistiocytosis: A Single-Center Experience Joanna Nelson, MD
Background. Hemophagocytic lymphohistiocytosis (HLH) is a rare hematologic disorder which is characterized by excessive immune activation. In adults, it is typically secondary to an underlying process such as autoimmune disease, infection, or malignancy. Guidelines based on expert opinion suggest prophylaxis (PPX) with antiviral, antibacterial, and/or antifungal agents for patients undergoing treatment for HLH; however, the incidence of infectious complications is not known. We aimed to study the scope of infection in patients with HLH to help determine the best strategy for antimicrobial PPX.
Methods. We performed a retrospective chart review of 56 adult patients who fulfilled clinical diagnostic criteria for HLH treated at Stanford University Hospital between 2012 and 2018. Infections diagnosed up to 1 month prior and up to 6 months after a diagnosis of HLH were reviewed.
Results. A total of 57 episodes of HLH in 56 patients were reviewed. Infection was determined to be the trigger of HLH in five cases (EBV in three cases, Histoplasma in one case, MAC or HHV6 in one case). Antiviral PPX was used in 72%, PCP PPX in 75%, and antifungal PPX in 77% of HLH episodes. At least one infectious complication occurred in 33 of 57 episodes of HLH (58%) with 69 total infections diagnosed after HLH diagnosis: 46 bacterial, 12 viral, and 11 fungal. Bacterial infections included bacteremia (43%), pneumonia (15%), skin and soft tissue (13%), intra-abdominal infection (11%), urinary tract infection (13%), and others (5%). Of the viral infections, CMV viremia was the most prevalent and occurred in four patients (7% of HLH episodes). Fungal infections occurred in 19% of HLH episodes and included four yeast and seven mold infections (five proven and two possible). Three of these cases were not receiving antifungal PPX prior to infection; the remaining eight were breakthrough infections.
Conclusion. Infectious complications of HLH are common, and likely result from a combination of host immune factors related to underlying disease and induced by immunosuppressive chemotherapy. Most noteworthy is the incidence of fungal infections which supports the use of antifungal PPX in this patient population. Even with this, breakthrough infection, including with opportunistic molds, is not uncommon.
